Jazz Pharmaceuticals plc — Director's Dealing 2018

Jun 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-06-01

Reporting Person: Young Matthew P. (EVP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-01	Ordinary Shares	M	5000	$58.72	Acquired	41268	Direct
2018-06-01	Ordinary Shares	S	5000	$170.0424	Disposed	36268	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-01	Non-Qualified Stock Option (right to buy)	$58.72	M	5000	Disposed	2023-05-02	Ordinary Shares (5000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes 65 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $170.0000 to $170.3100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: This non-qualified stock option is part of an option award granted on May 3, 2013. The ordinary shares subject to the option award vested over 4 years from the vesting commencement date of April 22, 2013, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of April 22, 2017.